Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1

AIDS

Volumn 28, Issue 3, 2014, Pages 317-323

  Heredia, Alonso ^a   Davis, Charles ^a   Amin, Mohammed N ^a   Le, Nhut M ^a   Wainberg, Mark A ^b   Oliveira, Maureen ^b   Deeks, Steven G ^c   Wang, Lai Xi ^a   Redfield, Robert R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; Cytosine analogs; Drug resistance; Emtricitabine; HIV 1; M184V mutation; Nucleoside analog reverse transcriptase inhibitors; Resource limited setting

Indexed keywords

ANTI-HIV AGENTS; CELLS, CULTURED; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV CORE PROTEIN P24; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LYMPHOCYTES; MUTATION, MISSENSE; REAL-TIME POLYMERASE CHAIN REACTION; STILBENES; VIRUS REPLICATION;

EID: 84894076809     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000168     Document Type: Article

References (44)

1. Praparattanapan J, Kotarathitithum W, Chaiwarith R, Nuntachit N, Sirisanthana T, Supparatpinyo K. Resistance-associated mutations after initial antiretroviral treatment failure in a large cohort of patients infected with HIV-1 subtype CRF01-AE. Curr HIV Res 2012; 10:647-652.
2. Parikh UM, Mellors JW. Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens. Future Microbiol 2012; 7:929-932.
3. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, et al. Global trends in antiretroviral resistance in treatmentnaive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250-1258.
4. Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa MY, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovircontaining first-line regimen. AIDS 2012; 26:1679-1684.
5. Cambiano V, Bertagnolio S, Jordan MR, Lundgren JD, Phillips A. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. J Infect Dis 2013; 207 (Suppl 2):S57-S62.
6. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 2013; 18:115-123.
7. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-805.
8. Palmer S, Shafer RW, Merigan TC. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy) propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother 1999; 43:2046- 2050.
9. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87- 94.
10. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 1998; 421:277-279.
11. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, et al. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 1998; 250:53-58.
12. Heredia A, Davis C, Redfield R. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J Acquir Immune Defic Syndr 2000; 25:246-255.
13. Horvath Z, Saiko P, Illmer C, Madlener S, Hoechtl T, Bauer W, et al. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol 2005; 33:329-335.
14. Heredia A, Davis CE, Reitz MS, Le NM, Wainberg MA, Foulke JS, et al. Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drugresistant HIV-1. J Infect Dis 2013; 208:2085-2094.
15. Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med 2005; 13:138-142.
16. Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, et al. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS 2010; 24:1013-1018.
17. Sarafianos SG, Das K, Clark AD Jr, Ding J, Boyer PL, Hughes SH, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci U S A 1999; 96:10027-10032.
18. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:4040- 4049.
19. Wei X, Liang C, Gotte M, Wainberg MA. Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology 2003; 311:202-212.
20. Gao L, Hanson MN, Balakrishnan M, Boyer PL, Roques BP, Hughes SH, et al. Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. J Biol Chem 2008; 283:9196-9205.
21. Loemba H, Brenner B, Parniak MA, Máayan S, Spira B, Moisi D, et al. Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana. Antivir Ther 2002; 7:141- 148.
22. Xu HT, Colby-Germinario SP, Huang W, Oliveira M, Han Y, Quan Y, et al. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2013; 57:5649-5657.
23. Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A 1993; 90:8925-8928.
24. Back NK, Berkhout B. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine- resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1997; 41:2484-2491.
25. Lu J, Ho CH, Ghai G, Chen KY. Resveratrol analog, 3, 4, 5, 4'- tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis 2001; 22:321-328.
26. Billard C, Izard JC, Roman V, Kern C, Mathiot C, Mentz F, et al. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leukem Lymph 2002; 43:1991- 2002.
27. Clouser CL, Chauhan J, Bess MA, van Oploo JL, Zhou D, Dimick-Gray S, et al. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett 2012; 22:6642-6646.
28. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001; 6:115-126.
29. Cong ME, Heneine W, Garcia-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007; 81:3037-3041.
30. Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Antiinfect Ther 2004; 2:147-151.
31. Harrigan PR, Stone C, Griffin P, Najera I, Bloor S, Kemp S, et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis 2000; 181:912-920.
32. Lanier ER, Ait-Khaled M, Scott J, Stone C, Melby T, Sturge G, et al. Antiviral efficacy of abacavir in antiretroviral therapyexperienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther 2004; 9:37-45.
33. Mayhew CN, Mampuru LJ, Chendil D, Ahmed MM, Phillips JD, Greenberg RN, et al. Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antivir Res 2002; 56:167- 181.
34. Clouser CL, Holtz CM, Mullett M, Crankshaw DL, Briggs JE, Chauhan J, et al. Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PloS One 2011; 6:e15840.
35. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5:493-506.
36. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011; 6:e19881.
37. Gao RY, Mukhopadhyay P, Mohanraj R, Wang H, Horvath B, Yin S, et al. Resveratrol attenuates azidothymidine-induced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytes. Molec Med Rep 2011; 4:151-155.
38. Touzet O, Philips A. Resveratrol protects against protease inhibitor- induced reactive oxygen species production, reticulum stress and lipid raft perturbation. AIDS 2010; 24:1437-1447.
39. Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci 2004; 93:2448-2457.
40. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32:1377-1382.
41. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70:9003-9011.
42. Patel KR, Andreadi C, Britton RG, Horner-Glister E, Karmokar A, Sale S, et al. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med 2013; 5:205ra133.
43. Augustin MA, Sanguansri L, Lockett T. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Ann N Y Acad Sci 2013; 1290:107-112.
44. Neves AR, Lucio M, Martins S, Lima JL, Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomed 2013; 8:177-187.